Table 2.
Nephrologists' knowledge and beliefs regarding NSFa
| Strongly Agree % (N) | Agree % (N) | Disagree % (N) | Strongly Disagree % (N) | Do Not Know % (N) | |
|---|---|---|---|---|---|
| I am knowledgeable about the evidence linking gadolinium to NSF. | 21.1 (36) | 69.0 (118) | 7.0 (12) | 0.6 (1) | 2.3 (4) |
| NSF can be severely debilitating. | 80.7 (138) | 18.7 (32) | 0 | 0 | 0.6 (1) |
| NSF can be life threatening. | 50.3 (86) | 39.8 (68) | 5.8 (10) | 1.2 (2) | 2.9 (5) |
| Gadolinium-containing MRI contrast is a cause of NSF. | 35.1 (60) | 57.9 (99) | 1.8 (3) | 0 | 5.3 (9) |
| Some brands of gadolinium contrast are more likely to cause NSF than others. | 24.0 (41) | 45.0 (77) | 5.8 (10) | 0.6 (1) | 24.6 (42) |
| A patient with stage 5 CKD administered a standard dose of gadolinium is at risk for developing NSF. | 57.9 (99) | 38.6 (66) | 1.8 (3) | 0 | 1.8 (3) |
| A patient with stage 4 CKD administered a standard dose of gadolinium is at risk for developing NSF. | 21.1 (36) | 64.9 (111) | 6.4 (11) | 0.6 (1) | 7.0 (12) |
| A patient with stage 3 CKD administered a standard dose of gadolinium is at risk for developing NSF. | 5.8 (10) | 44.4 (76) | 25.7 (44) | 6.4 (11) | 17.5 (30) |
| PD patients administered a standard dose of gadolinium are at higher risk for developing NSF than HD patients. | 12.3 (21) | 29.2 (50) | 14.6 (25) | 0 | 43.9 (75) |
MRI, magnetic resonance imaging.
a
N for each item is 171.